N/A N=40 Fibromyalgia Integrative Training for Teens
Juvenile Fibromyalgia
Primary: Average Pain Intensity — 6.26; 6.41; 4.69; 6.38 units on a scale — p=.011
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Clinical Evaluation of Silk'n Glide for Face
Hirsutism
Primary: 1. Comparison of Hair Counts Before Treatments to 4 and 12 Weeks Follow up Visits. — 83.3; 78.1 percentage of hair reduction
Phase 2 N=174 Efficacy and Safety Study of Elagolix Versus Placebo or Leuprorelin Acetate in Endometriosis
Endometriosis
Primary: Change From Baseline in the Monthly Mean Numerical Rating Score (NRS) for Endometriosis Pain — -0.35; -0.84; -1.00; -0.94 units on a scale — p=0.0464
Phase 3 N=758 PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin
Non Hodgkin Lymphoma
Primary: Overall Disease-Free Survival — 42.8; 43.1 Month — p=0.541
N/A N=417 Will Veterans Engage in Prevention After HRA-guided Shared Decision Making?
Health Risk Appraisal · Heart Disease · Prevention
Primary: Enrollment in Prevention Services — 91; 56 participants — p=<.0001
Phase 3 N=115 BAX 326 (rFIX) Continuation Study
Hemophilia B
Primary: Adverse Events Possibly or Probably Related to the Investigational Product — 2 Adverse Events
N/A N=116 Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control
Type 1 Diabetes Mellitus
Primary: Glycated Hemoglobin (HbA1c) — 8.84; 9.03; 9.24; 9.14 percentage of hemoglobin molecules — p=0.86
Phase 3 N=261 An Open-Label Phase 3 Study of BMN 165 for Adults With PKU Not Previously Treated w/ BMN 165
Phenylketonuria
Primary: Number of Participants With Hypersensitivity Adverse Reaction — 111; 119 Participants
Phase 3 N=32 Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
Hemophilia B
Primary: Degree of Hemorrhage Control by Treatment Regimen — 53; 116; 105; 74 Bleeding Episodes
Phase 1 N=16 A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.
Carcinoma, Non-Small-Cell Lung
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) During First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0 Participants
N/A N=77 BioMonitor 2 In-Office Setting Insertion Safety and Feasibility Evaluation With Device Functionality Assessment
Insertable Cardiac Monitor
Primary: Number of Participants With Insertion Procedure-related Adverse Event That Requires Additional Invasive Intervention to Resolve — 0 participants with a Primary Objective…
Phase 3 N=244 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
Influenza
Primary: Humoral Immune Response in Terms of Haemagglutination Inhibition (HI) Antibody Titers Against the Flu A/California/7/2009 (H1N1) Vaccine Strain — 5.7; 5.2; 9.9; 192.6…
N/A N=44 Pilot Study of a Computer-Based Intervention for Alcohol Misuse in the Emergency Department
Alcohol Consumption
Primary: Change in Youth Alcohol Use — -0.44; -0.88; -0.06; -0.96 units on a scale
Phase 2 N=4 A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease
Fabry Disease
Primary: Number Of Participants Who Experienced Severe Treatment-emergent Adverse Events (TEAEs) — 1 Participants
N/A N=40 To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
Skin Care
Primary: Frequency of Dermal Response Score at 15-30 Minutes Post Patch Removal — 0; 0; 0; 0 Participants